要闻！白菜贱如泥：滞销困境引何深思？

白菜贱如泥：滞销困境引何深思？

山东平度，10万斤大白菜滞销地里，白菜贱卖至一毛二一斤，无人问津；新疆石河子，菜农眼睁睁看着白菜烂在地里，只能无奈处理……

近年来，白菜价格屡屡陷入低谷，甚至出现滞销、贱卖的情况，这不仅给菜农带来了巨大损失，也引发了社会各界的广泛关注。白菜，作为餐桌上的常见菜蔬，为何会沦落至此？

多重因素叠加，白菜价格持续走低

今年白菜价格低迷的原因是多方面的。首先，暖冬导致白菜产量过剩。今年冬季，全国气温偏高，导致白菜生长周期延长，产量明显增加。同时，受去年白菜价格较高影响，今年种植白菜的农户增多，供给量进一步扩大。

其次，需求疲软也是导致白菜价格低迷的重要原因。近年来，随着居民消费水平的提高，人们对蔬菜的需求更加多元化，对白菜等传统蔬菜的需求有所下降。此外，新冠疫情的反复也对餐饮业造成了较大冲击，导致对蔬菜的需求进一步减少。

滞销困境凸显农业生产体系脆弱

白菜滞销、贱卖事件暴露了我国农业生产体系存在的脆弱性。小农户生产模式使得抗风险能力弱，一旦市场价格波动，就容易造成重大损失。此外，农业信息不对称也是导致白菜滞销的重要原因。许多菜农缺乏市场信息，盲目种植，导致供需失衡。

破解白菜困局，亟需多方合力

要破解白菜价格低迷、滞销的困局，需要多方合力，采取综合措施。政府层面要加强农业生产规划指导，引导农民调整种植结构，减少白菜等传统蔬菜的种植面积；同时，要完善农业信息服务体系，帮助菜农及时了解市场信息，提高抗风险能力。

农户也要转变观念，积极学习新技术，提高生产水平，种植更具市场竞争力的蔬菜品种。此外，加强冷链物流建设，畅通农产品流通渠道，也是减少白菜损耗、提高市场供应效率的重要举措。

白菜价格低迷、滞销事件给我们敲响了警钟，也引发了对我国农业生产体系的深刻反思。只有加快农业供给侧结构性改革，推动农业现代化发展，才能真正解决白菜困局，让农民丰收、让消费者得利。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.